Good afternoon and welcome to Markets Desk.
In the agricultural complex, soybeans came under meaningful pressure into Wednesday's close, with front-month contracts shedding between eight and a half and eleven and a quarter cents on the session. The national average cash price settled near ten dollars and ninety-five cents, while soymeal and soy oil futures also finished in the red, reflecting broad-based softness across the oilseed complex.
Shifting to biotech, Alnylam Pharmaceuticals has inked a partnership with Inceptive Nucleics, an artificial intelligence-driven biotech firm, in a deal valued at up to approximately two billion dollars. The agreement signals continued appetite among established RNA-focused drugmakers to integrate AI into the early stages of drug development, potentially compressing timelines and discovery costs.
And staying in the biotech space, Kyverna Therapeutics reported updated Phase one data from its COMPARE trial, evaluating miv-cel in patients with treatment-refractory rheumatoid arthritis. The results, presented Wednesday, add to a growing body of evidence around cell therapies targeting autoimmune conditions, and the market will be watching closely as the program advances toward its Phase two readouts.
That's the tape. Markets Desk, signing off the floor.
